The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J. (1985) · Biochemistry · doi:10.1021/bi00324a025 · Cited by 1,024
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
On the medicinal chemistry of gold complexes as anticancer drugs
Ott, I. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.019 · Cited by 825
Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes
Morris, R. E., Aird, R. E., del Socorro Murdoch, P., Chen, H., Cummings, J., Hughes, N. D., Parsons, S., Parkin, A., Boyd, G., Jodrell, D. I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010051m · Cited by 787
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Scolaro, C., Bergamo, A., Brescacín, L., Delfino, R., Cocchietto, M., Laurenczy, G., Geldbach, T. J., Sava, G., & Dyson, P. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050015d · Cited by 784
Metal-based antitumour drugs in the post genomic era
Dyson, P. J., & Sava, G. (2006) · Dalton Transactions · doi:10.1039/b601840h · Cited by 771
Exploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy
Ang, W. H., & Dyson, P. J. (2006) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200600723 · Cited by 713
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA
Reedijk, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737293100 · Cited by 617
Using coordination chemistry to design new medicines
Ronconi, L., & Sadler, P. J. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2006.11.017 · Cited by 608
Toxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini, A., & Messori, L. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.026 · Cited by 595
van Rijt, S. H., & Sadler, P. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.003 · Cited by 592
Aird, R. E., Cummings, J., Ritchie, A. A., Muir, M., Morris, R. E., Chen, H., Sadler, P. J., & Jodrell, D. I. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600290 · Cited by 582
Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins
Ohndorf, U.-M., Rould, M. A., He, Q., Pabo, C. O., & Lippard, S. J. (1999) · Nature · doi:10.1038/21460 · Cited by 565
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies
Nobili, S., Mini, E., Landini, I., Gabbiani, C., Casini, A., & Messori, L. (2010) · Medicinal Research Reviews · doi:10.1002/med.20168 · Cited by 503
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Bancroft, D. P., Lepre, C. A., & Lippard, S. J. (1990) · Journal of the American Chemical Society · doi:10.1021/ja00175a020 · Cited by 477
Tumour-inhibiting platinum complexes—state of the art and future perspectives
Jakupec, M. A., Galanski, M. S., & Keppler, B. K. (2003) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/s10254-002-0001-x · Cited by 434
Metal based drugs: from serendipity to design
Fricker, S. P. (2007) · Dalton Transactions · doi:10.1039/b705551j · Cited by 414
Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation
Romero-Canelón, I., & Sadler, P. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400835n · Cited by 396
Ruthenium metallopharmaceuticals
Clarke, M. J. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00025-5 · Cited by 396
Particular aspects of platinum compounds used at present in cancer treatment
Desoize, B., & Madoulet, C. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00219-0 · Cited by 393
Anti-cancer palladium complexes: a focus on PdX2L2, palladacycles and related complexes
Kapdi, A. R., & Fairlamb, I. J. S. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00063c · Cited by 379
Shubbar, E., Kovács, A., Hajizadeh, S., Parris, T. Z., Nemes, S., Gunnarsdóttir, K., Einbeigi, Z., Karlsson, P., & Helou, K. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-1 · Cited by 373
What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 370
Designing organometallic compounds for catalysis and therapy
Noffke, A. L., Habtemariam, A., Pizarro, A. M., & Sadler, P. J. (2012) · Chemical Communications · doi:10.1039/c2cc30678f · Cited by 370
Recognition of cisplatin adducts by cellular proteins
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00142-7 · Cited by 349
A categorization of metal anticancer compounds based on their mode of action
Gianferrara, T., Bratsos, I., & Alessio, E. (2009) · Dalton Transactions · doi:10.1039/b905798f · Cited by 336
Casini, A., Gabbiani, C., Sorrentino, F., Rigobello, M. P., Bindoli, A., Geldbach, T. J., Marrone, A., Re, N., Hartinger, C. G., Dyson, P. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8006678 · Cited by 270
Correlation between Cytotoxicity and DNA Binding of Polypyridyl Ruthenium Complexes
Novakova, O., Kasparkova, J., Vrana, O., van Vliet, P. M., Reedijk, J., & Brabec, V. (1995) · Biochemistry · doi:10.1021/bi00038a034 · Cited by 246
Targeted delivery of platinum-based anticancer complexes
Butler, J. S., & Sadler, P. J. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.01.004 · Cited by 237
Targeting Nucleus DNA with a Cyclometalated Dipyridophenazineruthenium(II) Complex
Huang, H., Zhang, P., Yu, B., Chen, Y., Wang, J., Ji, L., & Chao, H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501095r · Cited by 230
Monofunctional and Higher-Valent Platinum Anticancer Agents
Johnstone, T. C., Wilson, J. J., & Lippard, S. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400538c · Cited by 223
Oxaliplatin: Pharmacokinetics and Chronopharmacological Aspects
L??vi, F., Metzger, G., Massari, C., & Milano, G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00001 · Cited by 194
Mendoza-Ferri, M. G., Hartinger, C. G., Mendoza, M. A., Groessl, M., Egger, A. E., Eichinger, R. E., Mangrum, J. B., Farrell, N. P., Maruszak, M., Bednarski, P. J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8013234 · Cited by 185
Hartinger, C. G., Groessl, M., Meier, S. M., Casini, A., & Dyson, P. J. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35532b · Cited by 157
Becker, K., Herold‐Mende, C. C., Park, J. J., Lowe, G. M., & Schirmer, R. H. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm001014i · Cited by 150
Gold(III) compounds as anticancer drugs
Gabbiani, C., Casini, A., & Messori, L. (2007) · Gold bulletin · doi:10.1007/bf03215296 · Cited by 142
Jodrell, D. I., Evans, T. R. J., Steward, W. P., Cameron, D., Prendiville, J., Aschele, C., Noberasco, C., Lind, M., Carmichael, J., Dobbs, N. A., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.04.032 · Cited by 130
Antitumor activity of gold(III)‐dithiocarbamato derivatives on prostate cancer cells and xenografts
Cattaruzza, L., Fregona, D., Mongiat, M., Ronconi, L., Fassina, A., Colombatti, A., & Aldinucci, D. (2010) · International Journal of Cancer · doi:10.1002/ijc.25311 · Cited by 128
Pratesi, G., Perego, P., Polizzi, D., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690620 · Cited by 118
Bugarčić, Ž. D., Bogojeski, J., Petrović, B., Hochreuther, S., & van Eldik, R. (2012) · Dalton Transactions · doi:10.1039/c2dt31045g · Cited by 118
Self-citationBugarčić, Ž. D., Bogojeski, J., & van Eldik, R. (2015) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2015.02.016 · Cited by 114
Self-citationKljun, J., Bratsos, I., Alessio, E., Psomas, G., Repnik, U., Butinar, M., Turk, B., & Turel, I. (2013) · Inorganic Chemistry · doi:10.1021/ic401220x · Cited by 112
The development of platinum compounds and their possible combination
Pasetto, L. M., D'Andrea, M. R., Brandes, A. A., Rossi, E. G., & Monfardini, S. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.02.003 · Cited by 109
Milutinović, M. M., Simović, A. R., Bratsos, I., Klisurić, O. R., Vraneš, M., Gligorijević, N., Radulovic, S. S., & Bugarčić, Ž. D. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.10.001 · Cited by 100
Self-citationRodrigues, E. G., Silva, L. S., Fausto, D. M., Hayashi, M. S., Dreher, S., dos Santos, E. L., Pesquero, J. B., Travassos, L. R., & Caires, A. C. F. (2003) · International Journal of Cancer · doi:10.1002/ijc.11434 · Cited by 87
Lu, Q. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061416b · Cited by 85
Degradation of Bidentate-Coordinated Platinum(II)-Based DNA Intercalators by Reduced l -Glutathione
Kemp, S., Wheate, N., Pisani, M. J., & Aldrich-Wright, J. R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7016072 · Cited by 80
Darabi, F., Hadadzadeh, H., Simpson, J., & Shahpiri, A. (2016) · New Journal of Chemistry · doi:10.1039/c6nj01880g · Cited by 69
Harris, A. L., Ryan, J. J., & Farrell, N. P. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.018762 · Cited by 58
Tušek‐Božić, L., Matijašić, I., Bocelli, G., Calestani, G., Furlani, A., Scarcia, V., & Papaioannou, A. (1991) · Journal of the Chemical Society Dalton Transactions · doi:10.1039/dt9910000195 · Cited by 50
Zhang, C., Han, B.-J., Zeng, C.-C., Lai, S.-H., Li, W., Tang, B., Wan, D., Jiang, G., & Liu, Y. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.01.003 · Cited by 50
Giannini, F., Paul, L. E. H., Furrer, J., Therrien, B., & Süß‐Fink, G. (2013) · New Journal of Chemistry · doi:10.1039/c3nj00476g · Cited by 45
The effects of 56MESS on mitochondrial and cytoskeletal proteins and the cell cycle in MDCK cells
Garbutcheon‐Singh, K. B., Myers, S. J., Harper, B. W. J., Ng, N. S., Dong, Q., Xie, C., & Aldrich-Wright, J. R. (2013) · Metallomics · doi:10.1039/c3mt00023k · Cited by 34
Vranec, P., Potočňák, I., Sabolová, D., Kuchárová, V., Ipóthová, Z., Pisarčíková, J., & Paulíková, H. (2013) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2013.10.018 · Cited by 32
Corral, E., Hotze, A. C. G., Magistrato, A., & Reedijk, J. (2007) · Inorganic Chemistry · doi:10.1021/ic070092u · Cited by 22
Rosić, J., Petrović, B., Djuran, M. I., & Bugarčić, Ž. D. (2006) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-006-0568-z · Cited by 19
Self-citationEffect of carbon chain length on biological activity of novel palladium (II) complexes
Gao, E., Fu, H., Zhu, M., Ma, C., Liang, S.-K., Zhang, J., Li, L.-F., Wang, L., Li, Y., & Jiao, W. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.05.021 · Cited by 17
Gabano, E., Gama, S., Mendes, F., Gariboldi, M. B., Monti, E., Bombard, S., Bianco, S., & Ravera, M. (2013) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-013-1022-4 · Cited by 17
Cited by
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Gold, Silver, and Palladium Nanoparticles: A Chemical Tool for Biomedical Applications
Yaqoob, S. B., Adnan, R., Rameez Khan, R. M., & Rashid, M. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00376 · Cited by 308
Cyclobutanes in Small‐Molecule Drug Candidates
van der Kolk, M. R., Janssen, M. A. C. H., Rutjes, F. P. J. T., & Blanco‐Ania, D. (2022) · ChemMedChem · doi:10.1002/cmdc.202200020 · Cited by 274
Rah, B., Rather, R. A., Bhat, G. R., Baba, A. B., Mushtaq, I., Farooq, M., Yousuf, T., Dar, S. B., Parveen, S., Hassan, R., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.821344 · Cited by 202
Advances and perspectives of PARP inhibitors
Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0154-9 · Cited by 117
Metadata
- Authors
- Lazarević, T., Rilak, A., & Bugarčić, Ž. D.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 142
- Pages
- 8-31
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2605856867
- Cited by
- 428
- References
- 68
- FWCI
- 17.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.